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patients switching from older drug, Oxicam to new drugs, Coxibs. Deterministic 
model will help the hospital administrator understand pattern of drug use and its effect 
of ﬁ nancial management; however, clinical outcome should be included for further 
analysis. 
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
OUTCOME OF PHARMACIST INTERVENTION IN EDUCATION OF 
PATIENTS ON DUPLICATE PRESCRIPING HYPNOTIC-SEDATIVES
Chu LL1, Lin HC1, Huang HY1, Chan AL2
1Chimei Medical Center, Tainan, Taiwan; 2Chi Mei Medical Center, Tainan, Taiwan
OBJECTIVES: The inappropriate uses of hypnotic-sedatives will likely cause drug 
abuse. It has been known that patients visit different hospitals back and forth to get 
a duplicate prescription of hypnotic-sedatives. The purpose of this study is to explore 
the decrease of reﬁ ll frequency of prescribing sedative-hypnotics and drug cost. 
METHODS: This is a cohort study. Adult patients, who were prescribed two or more 
than two sedative-hypnotics with same pharmacological mechanism over a week by 
different physicians, will be retrieved from the claim database of a medical center in 
southern Taiwan. The retrieved patients were received a questionnaire to evaluate 
their knowledge about the appropriate use of hypnotic-sedatives before clinical phar-
macists provided patients with education for appropriate use of hypnotic-sedatives. 
The primary outcome was the reduction of total consumption on hypnotic-sedatives 
and drug cost before and after pharmacist education. RESULTS: A total of 100 
patients were included in this study. The results showed that about 62.8% of patients 
with duplicate use of hypnotic-sedatives were female and 59.1% of patients aged ³50 
years. Their chief complains was insomnia and/or anxiety which cannot be relieved 
by taking only one hypnotic-sedatives. The most frequently prescribed drugs in their 
duplicate prescription were zolpidem (30.45%), Fludiazepam (22.34%), Alprazolam 
(14.9%), Flunitrazepam (8.45%), and Brotizolam (7.93%). The average total con-
sumption on hypnotic-sedatives per day for each patient was decreased from 1.68 to 
1.33 tablets. The monthly hypnotic-sedatives costs were reduced form NT$ 21,000 
to NT $ 15,600. CONCLUSIONS: Pharmacist education on the appropriate use of 
hypnotic-sedatives and lifestyle management is likely to reduce the total consumption 
on hypnotic-sedatives and save drug costs. 
PND2
WARFARIN-ASSOCIATED INTRACRANIAL HEMORRHAGE
Yang SC, Lin HL, Chan AL
Chi Mei Medical Center, Tainan, Taiwan
OBJECTIVES: To explore the possibility of international normalized ratio 
(INR),drug—warfarin interactions exaggerated intracerebral hemorrhage. 
METHODS: This is an observational study. Patients who had diagnoses of intracra-
nial hemorrhage (ICH,ICD-9-CM codes 430, 431, 432.0, 432.1, 432.9) from January 
2004 to December 2009 were retrieved from the claim database of a medical center 
in southern Taiwan. We reviewed medical records to identify the possible relationship 
with suspected risk factors, drug-warfarin interactions and ICH. Patients who were 
not taking warfarin at the time of hemorrhage and traumatic ICH were excluded. 
Potential drug interactions were deﬁ ned according to online drug interaction database 
of Lexi-InteractTM. Data were analyzed by multivariate logistic modeling. RESULTS: 
During the study period, 24 patients were deﬁ ned as ICH while patients were receiving 
warfarin. Forty-ﬁ ve percent of patients had an INR value >3.0 at admission to hospital 
and 25% were exceeded 5.0. The potential drug-warfarin interaction were antiplate-
lets (41.6%), allopurinol (16.6%), amiodarone (8.3%), NSAID (16.6%), others 
(16.6%).which may increased the bleeding risk. Five patients of 24 patients were died 
within 2 weeks. No correlation between the fatal cases and their gender, age, INR 
value, smoking, alcohol and comorbid diseases was founded. CONCLUSIONS: 
Although no correlation between drug–warfarin interaction, INR and ICH was found 
in this study, physicians should still need to inform patients, who are taking warfarin, 
to concern the potential interactions between herbs and over-the-counter medicines. 
NEUROLOGICAL DISORDERS – Cost Studies
PND3
A RAPID REVIEW OF ECONOMIC EVALAUTIONS OF DONEPEZIL, 
RIVASTIGMINE, GALANTAMINE AND MEMANTINE FOR ALZHEIMER’S 
DISEASE (AD)
Feng J, Huang R, Pwee K
Ministry of Health, Singapore
OBJECTIVES: To review the cost-effectiveness of cholinesterase inhibitors (ChEIs; 
donepezil, galantamine and rivastigmine) and memantine for treating patients with 
AD. This review aims to inform policymakers in Singapore on the published cost-
effectiveness studies of these drug therapies. METHODS: Electronic databases 
(EMBASE, MEDLINE, NHS EED) were searched from inception to February 2010 
for published economic evaluation studies. Additional references were identiﬁ ed 
through searching bibliographies of included studies and related publications. Review 
papers of economic evaluations either on individual drugs or more of these drugs were 
considered. An outline assessment of economic evaluations was undertaken using 
Drummond’s checklist. RESULTS: A systematic search of the literature identiﬁ ed 32 
economic evaluations (2 of all three ChEIs, 11 of donepezil, 5 of rivastigmine, 7 of 
galantamine, and 7 of memantine). All studies used clinical trial data from single drug 
comparisons with placebo. Different approaches have been used to model disease 
progression for evaluating cost-effectiveness of each drug, making comparison 
between drugs more difﬁ cult. Caro et al. (2003) and Green et al. (2005) considered 
the three ChEIs using a common analytical framework. Most of the studies reported 
that drugs provided health beneﬁ ts and cost savings over time, suggesting that their 
use was cost-effective. However, Green et al. (2005) concluded that treatment with 
ChEIs may not be cost effective from the UK NHS’s perspective. CONCLUSIONS: 
The majority of economic evaluations of ChEIs and memantine reported that these 
treatments were the dominant strategies compared with no treatment. However, 
conclusions from the reviews of economic analyses were mixed, and the authors com-
mented that the ﬁ ndings from economic analyses of these four drugs should be 
interpreted with caution due to the assumptions and methodology used. Comparison 
between studies is difﬁ cult due to difference in study types, geographic locations, 
perspectives and different assumptions within the models. 
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
PRS1
RISK OF SERIOUS ASTHMA EXACERBATIONS ASSOCIATED WITH 
LONG-ACTING-BETA-AGONISTS AMONG MEDICAID PATIENTS WITH 
ASTHMA: A RETROSPECTIVE COHORT STUDY
Guo JJ1, Tsai K2, Kelton CM3, Bian B1, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA; 2Novartis Pharmaceutical Company, East 
Hanover,, NJ, USA; 3University of Cincinnati College of Business, Cincinnati, OH, USA
OBJECTIVES: Concerns have been raised that the use of long-acting-beta-agonists 
(LABAs) may be associated with an increased risk of serious exacerbations (SAEs). 
We proposed to examine the association between LABAs and SAEs among patients 
with asthma in a large Medicaid population. METHODS: A total of 1,117,850 
patients with asthma were selected for this study using a multi-state Medicaid claims 
database. The study period was January 1, 2002 to December 31, 2007. SAEs included 
any primary asthma diagnosis for either hospitalization, emergency room visits, or 
intubation. Major asthma medications included in the analysis were inhaled cortico-
steroids (ICS), LABAs, ICS/LABA combinations, short-acting-beta-agonists, leukotri-
ene modiﬁ ers, and methylxanthines. Asthma severity levels were deﬁ ned by patient’s 
treatment regimens based on the national asthma guideline. Cox proportional hazard 
regression was conducted to assess the risk of SAEs associated with the use of LABAs, 
ICS/LABA combinations, and other covariates. RESULTS: Based on the ﬁ rst 6 months 
of wash-out period, we identiﬁ ed 550,392 patients with newly diagnosed and 567,458 
patients with preexisting asthma. A total of 197,283 (35.8%) newly diagnosed and 
242,207 (42.7%) preexisting patients had at least one SAE during the study period. 
After controlling for covariates, the risk of SAEs was relatively low among newly 
diagnosed patients taking salmeterol (hazard ratio [HR] = 0.93, 95% conﬁ dence 
intervals [CI] 0.89–0.97), formoterol (HR = 0.88, 0.83–0.94), and ICS/LABA combi-
nation (HR = 0.88, 0.87–0.90). Meanwhile, the risk of SAEs was mixed among pre-
existing asthmatic patients taking salmeterol (HR = 1.03, 1.01–1.04), formoterol (HR 
= 0.94, 0.90–0.97), and ICS/LABA combination (HR = 1.01, 1.00–1.02). Other key 
risk factors (P < 0.0001) were associated with African-American, severe or moderate 
asthma, use of oral steroids, alcohol or substance disorder, depressive disorder, preg-
nant women, obesity, and upper respiratory tract infection. CONCLUSIONS: The 
risk of SAEs should be considered when treating patients with asthma, especially for 
patients with key comorbidities as well as African-American patients and pregnant 
women. 
PRS4
ASSESSMENT OF KNOWLEDGE ABOUT TUBERCULOSIS AMONG TB 
PATIENTS IN NORTH EAST LIBYA
Solliman M1, Ahmad Hassali MA1, Al-Haddad M1, Hadidan M2
1Universiti Sains Malaysia, Penang, Penang, Malaysia, 2Alfatih Medical Sciences University, 
Tripoli, Libya
OBJECTIVES: To evaluate the knowledge toward the etiology and treatment of Tuber-
culosis (TB) among TB patients in North Eastern Libya. METHODS: Face to face 
interview with all TB Patients in 2009 was conducted at Kuwaiﬁ a and Shahat Chest 
Hospitals in North Eastern Libya. Questionnaire included questions related to the 
knowledge about transmission, diagnosis; risk factors, treatment and prevention of TB. 
A total of 140 patients participated in this study. Knowledge scores ranged from zero 
(minimum score) to 23 (maximum score). All data was analyzed using SPSS version 
15.00®. Inferential statistics were used as whenever appropriate. P-value of less than 
0.05 was considered signiﬁ cant. RESULTS: Majority of the respondents were Libyans 
(n = 92, 65.7%). Fifty-ﬁ ve (39.3%) of the respondents were males, and up to 90 subjects 
(64.3%) were urban residents. Almost all of the respondents have heard about TB. 
Nearly (n = 70, 50.0%) shared a thought that the main source of their knowledge 
regarding TB were health workers, followed by television (n = 63, 45.0%), and family 
members (n = 34, 24.3%). Libyans have signiﬁ cantly better knowledge (12.26 ± 4.33) 
than non Libyans (7.85 ± 4.83, t = 30.12, P < 0.001). In addition those respondents 
with tertiary educations scored signiﬁ cantly higher knowledge score (15.7 ± 4.2) com-
pared to those of intermediate (15.3 ± 3.8) and illiterate (9.4 ± 3.5), [F = 30.12, P = 
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0.001]. Moreover, respondents from urban areas were found to have better knowledge 
(12.06 ± 3.82) than rural residents (8.38 ± 4.92, t = 20.0), (P = < 0.001). While, in term 
of level of income those with high income (12.37 ± 3.79) have signiﬁ cantly better 
knowledge than low income (8.00 ± 4.85), [F = 5.5, P < 0.001]. CONCLUSIONS: The 
level of knowledge about TB among TB patients was a low, Therefore, there is a need 
for massive health education campaign to be undertaken by policymakers in order to 
improve TB patients’ knowledge toward TB. 
PRS5
EVALUATING SAFETY OUTCOMES OF LONG-ACTING BETA AGONISTS 
(LABAS) IN PATIENTS WITH ASTHMA
Bian B1, Guo JJ1, Kelton CM2, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business, 
Cincinnati, OH, USA
OBJECTIVES: The use of long-acting beta agonists (LABAs) has raised safety concerns, 
especially the potential for severe asthma exacerbations (SAEs). The purpose of this 
review was to review the published safety outcomes researches about LABA therapy and 
compare disease epidemiologic trends. METHODS: A systematic literature review was 
conducted with the speciﬁ c focus on safety outcomes research from clinical trials, meta-
analyses, and post-marketing studies. Patients with asthma were reviewed and compared 
between races, and between age groups. SAEs were deﬁ ned as either asthma-related 
death, hospitalization or emergency room visits. Seven major studies were identiﬁ ed and 
reviewed. Annual mortality rate and SAE trends for asthmatic patients and subgroup 
of African American patients were compared. RESULTS: The prevalence of asthma 
increased from 5% in 1992 to 7.8% in 2006, while mortality rate decreased from 1.7 
per 100,000 in 1999 to 1.2 per 100,000 in 2006. Multiple clinical trial data showed 
that LABA monotherapy may be associated with increased risk of asthma exacerbation 
or asthma related death. On the other hand, meta-analyses showed that the use of LABA 
with ICS may be associated with positive outcomes including symptoms reduction, 
quality of life improvement, reduced rate of exacerbations and severe exacerbation. Due 
to the limited data, the relationship between LABAs and an increased risk of severe 
asthma exacerbation is unclear, especially in pediatric and African American patients. 
Due to safety concerns, the US FDA made several label changes to warn the public about 
LABA therapy and has requested more assessments of LABA use in asthma patients. 
CONCLUSIONS: The safety outcomes of the use of LABAs for the asthma treatment 
remain controversial. More well-design research is required to assess the risk of SAEs 
related to LABA therapy in different populations. 
RESPIRATORY-RELATED DISORDERS – Cost Studies
PRS6
BURDEN OF SMOKING RELATED MAJOR DISEASES IN INDIA: 
ESTIMATION OF DIRECT OUT-OF-POCKET COST
Kochhar P1, Arora M2, Menon S1, Selvaraj S2
1Pﬁ zer India, Mumbai, India, 2PHFI, New Delhi, India
OBJECTIVES: To estimate the direct out-of-pocket medical costs of treating major 
diseases attributable to smoking in India. METHODS: Indian data on burden of 
smoking related illnesses was compiled on lines of the BENESCO (Beneﬁ ts of smoking 
cessation on outcomes) model by secondary analysis of existing datasets from census 
and National Sample Survey (NSS), 2004. The prevalence of smoking(cigarettes and 
bidis) was estimated by adjusting census projected population data with smoking rate 
found in the National Family & Health Survey–3 (NFHS-3), 2005–2006. Data on age 
and gender-wise disease prevalence and unit cost of treatment of diseases was obtained 
from NSS. A prevalence-based, disease-speciﬁ c approach was used to estimate the 
direct medical costs of treating cancer and other tumors, bronchial asthma, tubercu-
losis, respiratory diseases, hypertension and coronary heart disease attributable to 
smoking. RESULTS: Analysis of data from NFHS–3 estimated that there were 98.2 
million male and 4 million female smokers in India between 15 to 49 years of age. A 
total of 1.1 million hospitalizations and 90.5 million outpatient visits for 6 major 
diseases among adults were attributed to smoking annually. The total annual direct 
out-of-pocket medical cost for treating 6 major diseases was found to be Indian 
National Rupees 198 billion (US$ 4.4b). The total cost attributable to smoking was 
estimated to be INR 46 billion (US$ 1b) (i.e., 23% of the total); INR 33.8 billion 
(US$ 761m) for outpatient care and INR 12.3 billion (US$ 276m) for inpatient care. 
The total annual smoking attributable cost of treatment was highest for heart disease 
at INR 14.5 billion (US$ 327m) followed by bronchial asthma INR 8.8 billion (US$ 
199m) and hypertension INR 8.6 billion (US$ 195m). CONCLUSIONS: The smoking 
epidemic in India is a major preventable public health problem. The direct out-of-
pocket medical costs of treating major diseases attributable to smoking are high. 
PRS8
THE EFFECT OF UNCONTROLLED ASTHMA ON HEALTH-RELATED 
QUALITY OF LIFE AND RESOURCE USE IN JAPAN AND THE UNITED 
STATES
DiBonaventura MD1, Arakawa I2, Fukuda T3, Nagae T4, Wagner JS1, Stankus A5
1Kantar Health, New York, NY, USA; 2GlaxoSmithKline K.K., Tokyo, Japan; 3Tokyo University, 
Tokyo, Japan 4York Pharma KK, Tokyo, Japan; 5Kantar Health, Princeton, NJ, USA
OBJECTIVES: The aim of the current study was to determine the burden of illness 
associated with uncontrolled asthma in both the United States and Japan. METHODS: 
Data were obtained from the 2009 US and 2008 Japan National Health and Wellness 
Surveys (NHWS), cross-sectional Internet-based surveys of adults. Only patients who 
were diagnosed with asthma were included in the analyses. Using the Asthma Control 
Test (ACT), each asthma patient was categorized as having controlled or uncontrolled 
asthma and these groups were compared on health-related quality of life (mental 
component summary (MCS) and physical component summary (PCS) scores of the 
SF-12v2), the number of emergency room (ER) visits, and the number of hospitaliza-
tions controlling for demographics (country, age, gender, ethnicity, income, education) 
and patient characteristics (BMI and Charlson comorbidity index) in multiple regres-
sion and generalized linear models. RESULTS: In Japan, 648 patients (3.2%) were 
diagnosed with asthma while 6481 patients (8.5%) were diagnosed with asthma in 
the United States. Even after adjusting for demographics and patient characteristics, 
those with uncontrolled asthma reported signiﬁ cantly lower levels of MCS scores (M-adj 
= 42.5 vs. 45.9, P < 0.0001). However, not only were PCS scores signiﬁ cantly lower 
among uncontrolled asthma patients (M-adj = 41.7 vs. 47.4, P < 0.0001), but the dif-
ferences between controlled and uncontrolled patients was signiﬁ cantly greater in the 
United States (b = 4.4, P < 0.0001). The number of hospitalizations (M-adj = 0.61 vs. 
0.23, P < 0.0001) and ER visits (M-adj = 0.51 vs. 0.24, P < 0.0001) were both signiﬁ -
cantly higher for those with uncontrolled asthma. The effect on ER visits was signiﬁ -
cantly stronger in the United States than in Japan (b = 8.2, P < 0.01). CONCLUSIONS: 
Although the prevalence of asthma in the United States and uncontrolled asthma was 
greater than that of Japan, uncontrolled asthma patients in both countries exhibited 
a signiﬁ cantly worse health outcome proﬁ le. 
PRS9
DRUG UTILIZATION EVALUATION OF COMBINED INHALER 
THERAPIES AMONG PATIENTS WITH AIRWAY DISEASES IN A 
2000-BED MEDICAL CENTER IN TAIWAN
Lin HW1, Yu IW2, Cheng WE2
1China Medical University, Taichung, Taiwan; 2China Medical University Hospital, Taichung, 
Taiwan
OBJECTIVES: Appropriate use of combined inhalation therapies for airway disease 
patients is likely to reduce the undesirable health utilization, improve patients’ health-
related quality of life, smooth the decline of pulmonary function and prevent the 
mortality. A secondary data analysis was performed to describe the utilization of two 
types of combined inhaler therapies among the patients diagnosed with airway diseases 
for quality improvement of medical care. METHODS: The claimed administration 
data with visits using two types of combined inhalers (four various dosages and dosage 
forms of Seretide and one Symbicort turbulaler) and the corresponding visits’ diseases 
and demographic information from the 2000-bed medical center afﬁ liated to a medical 
university in Taiwan were retrieved and analyzed. There were up to ﬁ ve diagnoses 
listed in the data set. The descriptive analysis was performed to examine the trends 
of different types of combined inhalers being prescribed for patients diagnosed with 
corresponding airway diseases (i.e., ICD9: 491, 492,493,494,496, 518) in the year of 
2009. RESULTS: Of 2495 patients being prescribed with the combined inhaler thera-
pies (accounted for 9273 total visits), male was dominated (57.7% vs. 42.3%), average 
age was 56.7 ( ± 22.1) year-old and more than 80% were prescribed by the pulmonary 
physicians. Less than 2% had experience of switching inhalers within 1 year. Only 
55.4% were prescribed with coded airway diseases (asthma and COPD accounted for 
25.2% and 21.96%, respectively). Further, 50.6% of them were prescribed with 
inhalers once or twice within 1 year. These prescribing patterns might encounter the 
“drug choice problems.” CONCLUSIONS: The prescribing patters of combined 
inhaler therapies seem problematic in this health setting and need to be examined 
persistently and periodically. To ensure appropriate usages of these inhalers, it is neces-
sary to further study the contributing factors and to investigate the possible resolutions 
to improve the quality of medical care. 
RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies
PRS10
RACE AND ETHNICITY IN EMERGENCY ROOM AND NON-URGENT 
CARE VISITS AMONG LATINO CHILDREN SUFFERING FROM ASTHMA
Chang J1, Patel I1, Ortega A2, Park YS1, Balkrishnan R1
1University of Michigan, Ann Arbor, MI, USA; 2University of California, Los Angeles, CA, 
USA
OBJECTIVES: To identify differences in health-care utilization by race and Latino 
ethnicity among children with asthma and determine the relative contribution of 
predisposing, enabling, and unobserved factors in explaining these differences. 
METHODS: The California Health Interview Survey (CHIS) is a non-institutionalized 
household survey of California residents conducted bi-annually since 2001. Cross-
sectional survey data were a0nalyzed to identify differences by race and Latino ethnicity 
among children with asthma. After adjustment for sample weights and design effects, 
over 400,000 samples in the 2007 CHIS were calculated for children with asthma. 
Disparities in health-care utilization across all race/ethnicity categories were analyzed 
using multivariate logistic regression and negative binomial regression analysis. 
RESULTS: Mexican children with asthma are over 100% more likely to have an 
emergency room (ER) visit in the previous year (P < 0.04) and 58% less likely to have 
a doctor visit (P < 0.049) compared to White children with asthma after controlling 
for confounding variables. Among ethnicity groups, Latino ethnicity is 72% more 
likely to have an ER visit in the previous year and 38% less likely to have a doctor 
visit compared to non-Latino ethnicity. Negative binomial regression results show that 
